E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

  • Law Blogs

Become a Fan

« Science Progress Article Examines Impact of Gene Patents on Research | Main | Monsanto Announces New Policy Regarding Roundup Ready® Seeds »

December 22, 2009

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83451ca1469e20120a77479ad970b

Listed below are links to weblogs that reference Amgen and Hoffman-LaRoche Settle Mircera® Litigation:

Comments

Great move for Amgen, good move for Roche, not so good for the US public: those Amgen patents will probably never see another obviousness-type double patenting challenge, since that's not grounds for a reexam, only court proceedings. But who else is going to bring a similar product to market in the next four years, who would have standing to put such a challenge before a court? Absent a generic biopharmaceuticals approval route, Roche spent over $1B developing its own product; is there anyone else out there in the process of spending that kind of money to bring a third product to market?

The bottom line is that US consumers are going to have to continue to shell out big bucks for Amgen's product for another 4.5 years.

Dear Humor:

Agreed that Amgen has secured "peace in the Epo patents' time" with this victory. It will be interesting to see what happens to Epo pricing when Roche's product hits the market.

Thanks for the comment.

The comments to this entry are closed.

August 2014

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31